Compare Deutsche Bank AG (DB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Regeneron Pharmaceuticals Inc — how do they compare? Deutsche Bank AG trades at $33.61 (market cap $63.13B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Deutsche Bank AG pays the higher dividend (3.47%). Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| DB | REGN | |
|---|---|---|
Market Cap | $63.13B | $76.40B |
Volume | 3,260,488 | 626,381 |
Sector | Financials | Health |
52-Week High | $41.56 | $852.03 |
52-Week Low | $28.37 | $557.73 |
Typical Hold Time | 80 Days | 107 Days |
Enterprise Value | $75.71B | $71.12B |
Dividend Yield | 3.47% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.55, down 4.5% amid concerns over Q3 investment banking revenue. The stock shows attractive valuation with P/E of 9.1 and P/B of 0.71, while fundamentals improved with 2025 net income reaching $6.93B. Technical indicators signal bearish momentum with price near support at $33. Recent news highlights management's focus on 2028 targets and wealth management growth.
The outlook remains mixed - strong fundamentals and undervaluation present opportunity, but near-term headwinds in investment banking and bearish technicals suggest caution. Key risks include revenue volatility and European economic pressures, while analyst consensus leans neutral with 57.6% hold ratings.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
